Idraak Ventures

Where We Invest

Global Capital, European Focus

Strong neurotech and neuroscience companies, especially in Europe, are frequently undercapitalized relative to their US peers, despite comparable science and teams.

Our map

Europe — primary investment focus

GCC/MENA — anchor and home region

Rest of world — opportunistic

Stage focus

Stage Focus

1

Seed

Foundational capital at company inception.

2

Series A

Scaling validated science into product.

3

Series B

Building market infrastructure and revenue.

$50M target fund — currently being raised, not yet deployed.

Capital flows globally. Value compounds locally.

Most investment capital is deployed internationally, especially in Europe. Ecosystem value — the incubator, NeurotechMag Pro access, education, and the annual summit — is built in the GCC.

For many portfolio companies, that includes bringing their technology and, where it fits, their operations directly into the GCC. See Regional Deployment for more.